ArticleMethods in molecular biology (Clifton, N.J.)2026
Computer-Aided Discovery of Drugs Against Chagas Disease.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrating Molecular Similarity and AlphaFold-Based Structural Alignment for Target Discovery inPharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chagas disease affects around 6-8 million people worldwide. The available treatments have considerable limitations, including their uncertain efficacy in the chronic phase of the disease in adults, their unfavorable safety profile that usually compromises adherence to treatment, their long duration, and the emergence of resistant strains. All these considerations justify the continuous search for improved therapies.Informatics has been increasingly integrated into all levels of biomedical sciences, including the discovery and development of new drugs. In silico methods are relevant in all domains of therapeutics, but especially in the field of neglected diseases, in which their adoption can leverage the active participation of low- and middle-income countries (the ones historically affected by these diseases) in the development of new diagnostic and therapeutic options.This chapter describes the in silico methodologies that can be used to validate new pharmacological targets, compile data sets to train and/or validate computational models to apply in in silico screening campaigns, and implement retrospective and prospective in silico screening experiments.
Indexed as
Identifiers
41182607What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.